← Human Trials & Peer-Reviewed Studies
Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH): protocol for a phase II double-blind randomised controlled feasibility trial
Plain-language guide to PMID 33172941 (2020): randomized and double-blind clinical study of Vasopressin and Desmopressin in 50 patients.
Key Facts
- PMID
- 33172941
- Journal
- BMJ open
- Year
- 2020
- Study type
- Clinical Study
- Authors
- Desborough MJR et al. (10 authors)
- DOI
- 10.1136/bmjopen-2020-037555
What This Study Did, in Plain Language
What Was Tested
This clinical study looks at Vasopressin and Desmopressin.
The Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH) trial received ethical approval from the East Midlands-Nottingham 2 research ethics committee (18/EM/0184).
The DASH trial is funded by National Institute for Health and Care Research RfPB grant: PB-PG-0816-20011.
Who Took Part
The study group was 50 patients.
The researchers will mask participants, relatives and outcome assessors to treatment allocation.
Feasibility outcomes include proportion of patients approached being randomised, number of patients receiving allocated treatment, rate of recruitment and adherence to treatment and follow-up.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Vasopressin study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with Vasopressin could be set against what happens without it.
What Was Measured
PubMed files the paper under topics including Clinical Trials, Phase II as Topic, Deamino Arginine Vasopressin, Feasibility Studies, Platelet Aggregation Inhibitors, Quality of Life, Randomized Controlled Trials as Topic and Stroke.
Author keywords: anticoagulation, bleeding disorders & coagulopathies and stroke medicine.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vasopressin and Desmopressin in 50 patients.
The publication is from 2020 (BMJ open), a journal based in England.
More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.
Our Notes on the Compounds
Vasopressin: A 9-amino-acid hormone (antidiuretic hormone) that controls water balance and blood vessel tone; used in septic shock.
Desmopressin: A synthetic vasopressin analog (DDAVP) used for bedwetting, diabetes insipidus and some bleeding disorders.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.